Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) has issued an announcement.
On May 17, 2026, Nanobiotix reported early Phase 2 data from Part 1 of its CONVERGE trial, sponsored by Johnson & Johnson, evaluating JNJ-1900 (NBTXR3) in combination with chemoradiation and durvalumab in patients with unresectable stage 3 non-small cell lung cancer. The first patient was dosed in January 2025, and preliminary results in seven patients presented at ESTRO 2026 indicated that intratumoral or intranodal administration of JNJ-1900 is feasible and can be performed safely alongside standard-of-care therapy.
Initial efficacy readouts after the full regimen showed an objective response rate of 85.7%, a complete response rate of 57.1%, and a disease control rate of 100%, while earlier March 2026 data at first disease evaluation post-chemoradiotherapy but before anti-PD-L1 therapy showed a 71.4% objective response rate and 100% disease control. Although management cautioned that these signals are based on a small patient cohort and remain preliminary, the results support continued development of JNJ-1900 in locally advanced unresectable NSCLC, potentially enhancing Nanobiotix’s position in the oncology therapeutics market if benefits are confirmed in the randomized proof-of-concept phase.
The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a France-based biotechnology company focused on developing radioenhancer therapies for cancer, notably its nanoparticle-based candidate JNJ-1900 (NBTXR3). Through collaborations including an agreement with Johnson & Johnson’s Janssen unit, the company targets solid tumors such as non-small cell lung cancer, aiming to improve outcomes from standard chemoradiation and immunotherapy regimens.
Average Trading Volume: 76,394
Technical Sentiment Signal: Buy
Current Market Cap: $2.4B
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.